WO2018026212A3 - 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도 - Google Patents

섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도 Download PDF

Info

Publication number
WO2018026212A3
WO2018026212A3 PCT/KR2017/008399 KR2017008399W WO2018026212A3 WO 2018026212 A3 WO2018026212 A3 WO 2018026212A3 KR 2017008399 W KR2017008399 W KR 2017008399W WO 2018026212 A3 WO2018026212 A3 WO 2018026212A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
disease model
producing
fibrosis disease
stem cell
Prior art date
Application number
PCT/KR2017/008399
Other languages
English (en)
French (fr)
Other versions
WO2018026212A2 (ko
Inventor
조이숙
이미옥
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2018026212A2 publication Critical patent/WO2018026212A2/ko
Publication of WO2018026212A3 publication Critical patent/WO2018026212A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03046—Fructose-2,6-bisphosphate 2-phosphatase (3.1.3.46)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 섬유증 세포 유래 유도만능줄기세포 (iPSC)를 중간엽줄기세포 (MSC)로 분화시키는 단계 및 중간엽줄기세포를 스페로이드 (spheroid)로 배양하는 단계를 포함하는, 섬유증 질환 모델의 제조방법을 제공한다. 상기 섬유증 질환 모델의 제조방법은 섬유증 관련 콜라겐의 축적과 분해의 과정을 밝히는데 제한이 있었던 기존의 2D 제조방법보다 시간적, 공간적인 면에서 우수하며, 이를 더 정교하게 재현할 수 있는 섬유증 질환 특이적인 모델을 제공할 수 있다. 또한, 상기 제조방법으로부터 제조된 모델은 콜라겐 축적 억제용 제제의 스크리닝 및 섬유증 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2017/008399 2016-08-05 2017-08-03 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도 WO2018026212A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160100282A KR101844519B1 (ko) 2016-08-05 2016-08-05 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도
KR10-2016-0100282 2016-08-05

Publications (2)

Publication Number Publication Date
WO2018026212A2 WO2018026212A2 (ko) 2018-02-08
WO2018026212A3 true WO2018026212A3 (ko) 2018-03-29

Family

ID=61073758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008399 WO2018026212A2 (ko) 2016-08-05 2017-08-03 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도

Country Status (2)

Country Link
KR (1) KR101844519B1 (ko)
WO (1) WO2018026212A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102146127B1 (ko) * 2018-05-04 2020-08-19 서울대학교산학협력단 폐 섬유증 동물 모델 및 이의 용도
JP7425092B2 (ja) * 2020-01-15 2024-01-30 富士フイルム株式会社 抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法
CN113337454B (zh) * 2021-07-21 2023-02-21 中国人民解放军总医院第五医学中心 3d肝纤维化模型的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150089203A (ko) * 2014-01-27 2015-08-05 한국과학기술원 코스텔로 증후군의 유도-만능 줄기세포 모델 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150089203A (ko) * 2014-01-27 2015-08-05 한국과학기술원 코스텔로 증후군의 유도-만능 줄기세포 모델 및 이의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERARDIS, SILVIA: "Use of mesenchymal stem cells to treat liver fibrosis :current situation and future prospects", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 21, no. 3, 21 January 2015 (2015-01-21), pages 742 - 758, XP055604591 *
LEE, MI-OK: "Pro-fibrotic effects of PFKFB4-mediated glycolytic reprogramming in fibrous dysplasia", BIOMATERIALS, vol. 107, 26 August 2016 (2016-08-26), pages 61 - 73, XP029733980 *
VAN BEUGE, MARIKE MARJOLIJN: "Enhanced effectivity of an ALK5-inhibitor after cell -specific delivery to hepatic stellate cells in mice with liver in jury", PLOS ONE, vol. 8, no. 2, e56442, 18 February 2013 (2013-02-18), pages 1 - 9, XP055604603 *
WANG, JIANXUN: "Reduced cardiac fructose 2, 6 bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction", PLOS ONE, 7 January 2013 (2013-01-07), XP055604598 *
ZHANG, XUAN: "3D Spheroid culture enhances the expression of antifibrotic factors in human adipose-derived MSCs and improves their therapeutic effects on hepatic fibrosis", STEM CELLS INTERNATIONAL, vol. 2016, 28 February 2016 (2016-02-28), pages 1 - 8, XP055604593 *

Also Published As

Publication number Publication date
KR20180016179A (ko) 2018-02-14
KR101844519B1 (ko) 2018-04-02
WO2018026212A2 (ko) 2018-02-08

Similar Documents

Publication Publication Date Title
MY193954A (en) Method for manufacturing ciliary margin stem cells
WO2018026212A3 (ko) 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도
PH12016500783A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
WO2012030539A3 (en) Differentiation of human embryonic stem cells
SA517380984B1 (ar) طريقة لإنتاج خلايا سليفة في كبد بالغ
WO2014100779A8 (en) Methods for production of platelets from pluripotent stem cells and compositions thereof
MX369514B (es) Metodo para producir celulas progenitoras hepaticas adultas.
WO2012030538A3 (en) Differentiation of human embryonic stem cells
WO2019014310A8 (en) Biological methods for preparing terpenes
DE602006017833D1 (de) Lebervorläuferzellen
MX2019007782A (es) Una variante de isopropilmalato sintasa novedosa y un procedimiento de producción de l-leucina usando la misma.
NZ630680A (en) Selection of symbiota by screening multiple host-symbiont associations
PH12014501175B1 (en) Medium composition for rejuvenating stem cells
MX2018010828A (es) Medio para formar colonias y uso de este.
MY189592A (en) Method for producing cerebellar progenitor tissue
WO2015004539A3 (en) Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins ln-511, ln-521 and ln-221
MY184796A (en) Method for manufacturing ciliary marginal zone-like structure
WO2009028338A1 (ja) 新規オキシダーゼ遺伝子、および該遺伝子を利用する３－インドールピルビン酸の製造方法
WO2015108944A3 (en) Stem cell-derived hepatocytes in co-culture and uses thereof
WO2015064805A8 (ko) 중간엽 줄기세포로부터 유도된 만능 줄기세포를 이용하여 연골세포로 분화시키는 방법
WO2015056258A3 (en) Method of obtaining terminally differentiated neuronal lineages and uses thereof
WO2015042125A3 (en) Methods and compositions for producing hepatocyte-like cells
MX2013011153A (es) Metodo para el analisis de conformacion por presion.
MX2018015234A (es) Métodos para mejorar la transformación genética de sorgo.
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17837263

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17837263

Country of ref document: EP

Kind code of ref document: A2